Landscape Capital Management L.L.C. Makes New $2.56 Million Investment in Nektar Therapeutics $NKTR

Landscape Capital Management L.L.C. bought a new position in Nektar Therapeutics (NASDAQ:NKTR) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 60,431 shares of the biopharmaceutical company’s stock, valued at approximately $2,555,000. Landscape Capital Management L.L.C. owned approximately 0.30% of Nektar Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of NKTR. AQR Capital Management LLC boosted its stake in Nektar Therapeutics by 336.9% in the first quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock worth $2,463,000 after buying an additional 2,807,595 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in Nektar Therapeutics in the first quarter worth approximately $68,000. Rhumbline Advisers boosted its stake in Nektar Therapeutics by 23.3% in the first quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 41,948 shares in the last quarter. Marshall Wace LLP purchased a new stake in Nektar Therapeutics in the second quarter worth approximately $367,000. Finally, Headlands Technologies LLC purchased a new stake in Nektar Therapeutics in the second quarter worth approximately $65,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Stock Performance

NASDAQ:NKTR opened at $59.38 on Monday. The firm has a market cap of $2.01 billion, a PE ratio of -7.05 and a beta of 1.13. The business has a 50 day moving average price of $74.59 and a 200-day moving average price of $62.24. Nektar Therapeutics has a fifty-two week low of $7.99 and a fifty-two week high of $109.00.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing analysts’ consensus estimates of ($1.58) by ($0.24). The business had revenue of $10.86 million for the quarter, compared to the consensus estimate of $10.69 million. Nektar Therapeutics had a negative net margin of 284.18% and a negative return on equity of 85.40%. Research analysts predict that Nektar Therapeutics will post -9.45 EPS for the current year.

Analysts Set New Price Targets

NKTR has been the subject of several research reports. HC Wainwright upped their target price on Nektar Therapeutics from $165.00 to $185.00 and gave the stock a “buy” rating in a research note on Monday, April 20th. B. Riley Financial reaffirmed a “buy” rating and issued a $150.00 target price (up from $105.00) on shares of Nektar Therapeutics in a research note on Monday, February 23rd. Wedbush cut their target price on Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, May 11th. Wall Street Zen raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. Finally, Piper Sandler upped their target price on Nektar Therapeutics from $105.00 to $192.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $149.63.

Insider Activity at Nektar Therapeutics

In related news, CEO Howard W. Robin sold 444 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $65.51, for a total transaction of $29,086.44. Following the completion of the transaction, the chief executive officer owned 75,045 shares in the company, valued at $4,916,197.95. This represents a 0.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.50% of the stock is currently owned by corporate insiders.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.